← All trials
NCT06606067
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 3, 2024
- Primary completion
- Jul 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- Sep 20, 2024
- Last posted
- Sep 20, 2024
- Enrollment
- 294
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Institut Hospital del Mar d'Investigacions MèdiquesLead sponsor
- Universidad Carlos III MadridCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.